放疗结束时PSA作为前列腺癌根治性放疗联合雄激素剥夺治疗患者的新型预后因素
本研究纳入1993至2006年在本机构由同一医生连续接受根治性放疗且具有放疗结束时(EOR)PSA的前列腺癌患者688例,中位随访11.2年。EOR PSA可检测(≥0.1 ng/ml)与更差的10年生化失败无生存、无转移生存、前列腺癌特异性生存和总生存相关;在NCCN中高危接受放疗联合ADT者中,可检测EOR PSA与PCSS的关联强于初始NCCN危险度。
要点
- 放疗结束时PSA可检测(≥0.1 ng/ml)与更差的10年BFFS、MFS、PCSS和OS相关。
- 在NCCN中高危接受放疗联合ADT者中,可检测EOR PSA与PCSS的关联强于初始NCCN危险度。
- EOR PSA能否用于调整治疗强度尚需进一步研究。
核心结论
- 在接受根治性放疗和ADT的男性中,EOR PSA与生存终点显著相关。
- EOR PSA能否用于调整治疗强度尚需进一步研究。
研究设计与样本
- 1993至2006年在本机构由同一医生连续接受根治性放疗且具有EOR PSA的前列腺癌患者688例,中位随访11.2年。
- 分析放疗最后一周获得的EOR PSA水平与生存结局的关联,构建多变量校正Cox比例风险模型评估可检测EOR PSA(定义为≥0.1 ng/ml)与BFFS、MFS、PCSS和OS的关联。
- 构建Kaplan-Meier生存曲线并按EOR PSA分层。
主要发现
- 放疗结束时30%的患者PSA不可检测。
- 可检测EOR PSA者与不可检测者相比,10年BFFS为49.7% vs 64.4%(P<0.001)。
- 可检测EOR PSA者与不可检测者相比,10年MFS为84.8% vs 92.0%(P=0.003)。
- 可检测EOR PSA者与不可检测者相比,10年PCSS为94.3% vs 98.2%(P=0.007),10年OS为75.8% vs 82.5%(P=0.01)。
- 在NCCN中高危接受根治性放疗和ADT者中,可检测EOR PSA与PCSS的关联强于初始NCCN危险度:EOR PSA HR 5.89(95% CI 2.37-14.65,P<0.001),NCCN危险度 HR 2.01(95% CI 0.74-5.42,P=0.168)。
关键数值与推荐
- 可检测EOR PSA定义为≥0.1 ng/ml。
- EOR PSA在放疗最后一周获取。
临床怎么用
- 原文未据此给出推荐。
局限性
- 主要研究局限为回顾性研究设计及相关偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In men undergoing definitive radiation for prostate cancer, it is unclear whether early biochemical response can provide additional prognostic value beyond pre-treatment risk stratification. METHODS: Prostate cancer patients consecutively treated with definitive radiation at our institution by a single provider from 1993 to 2006 and who had an end-of-radiation (EOR) PSA (n=688, median follow-up 11.2 years). We analyzed the association of an EOR PSA level, obtained during the last week of radiation, with survival outcomes. Multivariable-adjusted cox proportional hazards models were constructed to assess associations between a detectable EOR PSA (defined as ⩾0.1 ng ml-1) and biochemical failure-free survival (BFFS), metastasis-free survival (MFS), prostate cancer-specific survival (PCSS) and overall survival (OS). Kaplan-Meier survival curves were constructed, with stratification by EOR PSA. RESULTS: At the end of radiation, the PSA level was undetectable in 30% of patients. Men with a detectable EOR PSA experienced inferior 10-year BFFS (49.7% versus 64.4%, P<0.001), 10-year MFS (84.8% versus 92.0%, P=0.003), 10-year PCSS (94.3% versus 98.2%, P=0.007) and 10-year OS (75.8% versus 82.5%, P=0.01), as compared to men with an undetectable EOR PSA. Among National Comprehensive Care Network (NCCN) intermediate- and high-risk men who were treated with definitive radiation and androgen deprivation therapy (ADT), a detectable EOR PSA was more strongly associated with PCSS than initial NCCN risk level (EOR PSA: HR 5.89, 95% CI 2.37-14.65, P<0.001; NCCN risk level: HR 2.01, 95% CI 0.74-5.42, P=0.168). Main study limitations are retrospective study design and associated biases. CONCLUSIONS: EOR PSA was significantly associated with survival endpoints in men who received treatment with definitive radiation and ADT. Whether the EOR PSA can be used to modulate treatment intensity merits further investigation.
引用
- Narang AK, Trieu J, Radwan N, et al. End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2017. PMID: 28094250. doi:10.1038/pcan.2016.67
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。